Please assess the completion status of the following clinical trial:

Trial Title: Combination of Alemtuzumab and Rituximab at Low-doses in Refractory Chronic Graft-Versus-Host Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with chronic graft-versus-host disease.~* Patients over 18 years old.~* Patients who received first-line treatment with no response (failure), relapse or steroid dependance.~Exclusion Criteria:~* Patients with active bacterial or viral infections.~* Patients with hematologic disease progression.~* Patient's intolerance to drugs.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Alemtuzumab and rituximab (Type: EXPERIMENTAL): Patients with chronic GVHD after first-line therapy failure will receive Alemtuzumab at 10mg subcutaneously daily for 3 doses (days 1, 2 and 3) Rituximab at 100mg intravenously weekly for 4 doses (days 4, 11, 18 and 25. THE STUDY HAVE ONLY ONE ARM.

Based on this trial design, predict the completion outcome and termination type (if applicable).